Roche's Tiragolumab Fails in Phase 3 Test, Poses Questions on TIGIT Strategy

Roche's tiragolumab, a cancer immunotherapy targeting the TIGIT protein, faced setbacks as it failed to achieve its primary goal in the pivotal Phase 3 SKYSCRAPER-01 trial. The study, which evaluated the combination of tiragolumab with Roche's Tecentriq in patients with high PD-L1 non-small cell lung cancer (NSCLC), did not extend the survival of participants[1][2]. Despite earlier interim data that hinted at potential benefits, the final results disappointed, without statistically significant improvement in overall survival[2]. Roche remains dedicated to evaluating its TIGIT strategy through ongoing and future studies, despite this setback, while also pursuing new avenues like a $1.5 billion acquisition to enhance its oncology portfolio with CAR-T cell therapies[1][2].